DBV Technologies Q4 2024 Earnings Report

DBV Technologies EPS Results

• Actual EPS: -$1.10
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

DBV Technologies Revenue Results

• Actual Revenue: $0.51 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

DBV Technologies Announcement Details

• Quarter: Q4 2024
• Date: 4/11/2025
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

DBV Technologies (NASDAQ:DBVT) is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapy solutions for food and environmental allergies. At the core of its research is the Viaskin® platform, an epicutaneous patch technology designed to deliver micro-doses of allergen through intact skin to elicit desensitization while minimizing systemic exposure. The company’s lead program, Viaskin Peanut, is being evaluated in pivotal Phase III trials in both the United States and Europe, offering a novel approach to addressing one of the most common and potentially severe food allergies in children and adults.

Beyond its peanut allergy program, DBV Technologies is advancing additional Viaskin immunotherapies targeting cow’s milk allergy, atopic dermatitis associated with food allergies, and other allergens such as hen’s egg and cat dander. These programs are at various stages of clinical development, highlighting the platform’s versatility and the company’s commitment to addressing unmet medical needs in allergy care. DBV collaborates with leading academic institutions and regulatory authorities to design and execute trials that meet rigorous safety and efficacy standards.

Founded in 2002 and headquartered in Bagneux, France, DBV Technologies also maintains a presence in Marlborough, Massachusetts, to support its North American operations. The company was co-founded by renowned allergists and scientists, and its leadership team is headed by CEO Marco Zannoni, whose experience spans global product development and regulatory strategy. DBV’s scientific advisory board comprises experts in allergy and immunology, reinforcing its strategic vision to transform the treatment landscape for allergic diseases worldwide.